According to report titled ‘Global Psoriasis Treatment Market - Analysis By Type, By Treatment Method, By Region, By Country (2020 Edition): Market Insights and Outlook Post Covid-19 Pandemic (2020-2025)’, available with Market Study Report, global psoriasis treatment market was valued USD 16.7 billion in 2019 and is projected to register a healthy growth rate over 2020-2025.
 

Rising number of patients with psoriasis, increasing research and investments for development of biological treatment, booming geriatric population, and government initiatives aimed at raising awareness about the disease are the major factors driving the industry growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2827956/
 

Experts claim that growing number of various drugs at clinical stages and their commercialization in the next 3-5 years are expected to accelerate worldwide psoriasis treatment progress. In fact, Arcutis has developed the most promising candidate for treating scalp psoriasis, the ARQ-154 Foam.
 

Besides, adoption of unhealthy lifestyle such as excess intake of alcohol and smoking tobacco are increasing the cases of psoriasis as well as psoriasis arthritis, subsequently enhancing the demand for treatment and medication of these conditions.
 

Elaborating on the Covid-19 impact, the market progress was hindered in 2020 as all businesses were temporarily closed to curb the spread of the virus. The National Psoriasis Foundation the Medicare extended the inclusion of immunosuppressant medications, which IPC initially recommended it to be discontinue or postponed by physicians for psoriasis patients, in telehealth administrations amid the pandemic, in turn, supported in the industry growth a while.
 

Based on type, global psoriasis treatment market is fragmented into inverse psoriasis, plague psoriasis, pustular psoriasis, guttate psoriasis, and erythrodermic psoriasis. Among these, plague psoriasis segment is touted to record strong gains in the forthcoming years, attributable to ongoing development of a significant number of treatments for the disease.
 

Considering the geographical scope, Asia Pacific industry size is anticipated to expand considerably over the forecast duration, creditable to presence of a large target population, growing healthcare expenditure, and favorable government initiatives.
 

Speaking of the competitive landscape, Johnson & Johnson, Amgen Inc., Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Bausch Health Companies Inc., Almirall S.A., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., and UCB S.A are the top-tier players in worldwide psoriasis treatment industry sphere.